Drug Profile
Research programme: immunoconjugates - Iksuda Therapeutics
Latest Information Update: 28 Oct 2022
Price :
$50
*
At a glance
- Originator Glythera
- Developer Iksuda Therapeutics
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Cyclin-dependent kinase inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical B-cell lymphoma
- No development reported Solid tumours
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for preclinical development in Solid-tumours in United Kingdom (Parenteral)
- 07 Jun 2021 Iksuda Therapeutics plans a first-in-human phase I trial for Cancer (Parenteral)
- 15 Jun 2020 Preclinical trials in B-cell lymphoma in United Kingdom (Parenteral), prior to June 2020 (Iksuda Therapeutics pipeline, June 2020)